Last reviewed · How we verify
adapalene gel, 0.3%
Adapalene is a third-generation retinoid that binds to retinoic acid receptors (RARs) to normalize skin cell differentiation and reduce inflammation.
Adapalene is a third-generation retinoid that binds to retinoic acid receptors (RARs) to normalize skin cell differentiation and reduce inflammation. Used for Acne vulgaris, Photoaging and fine wrinkles (off-label use in some regions).
At a glance
| Generic name | adapalene gel, 0.3% |
|---|---|
| Also known as | Differin® 0.3% Gel, Differin® Gel, 0.3% |
| Sponsor | Galderma R&D |
| Drug class | Retinoid (third-generation) |
| Target | Retinoic acid receptors (RARγ, RARα, RARβ) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Adapalene selectively activates retinoic acid receptor gamma (RARγ) and other RAR subtypes, promoting keratinocyte differentiation and reducing sebum production. It decreases comedone formation and has anti-inflammatory properties, making it effective for treating acne by normalizing follicular epithelial desquamation and reducing bacterial colonization.
Approved indications
- Acne vulgaris
- Photoaging and fine wrinkles (off-label use in some regions)
Common side effects
- Erythema
- Scaling/peeling
- Dryness
- Pruritus
- Photosensitivity
Key clinical trials
- Experience With Topical Acne Treatment (EARLY_PHASE1)
- Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel (PHASE2)
- A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne (PHASE4)
- A Treatment for Severe Inflammatory Acne Subjects (PHASE4)
- Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars (PHASE4)
- Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris (PHASE4)
- Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage (PHASE3)
- Effects of Oral Zinc Gluconate Among Acne Vulgaris Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |